AMIODARONE" LUNG: LITERATURE REVIEW AND AUTHORS' OWN OBSERVATIONS


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Until now, amiodarone is widely used worldwide antiarrhythmic drug due to its therapeutic effectiveness. However, the relatively high incidence of side effects complicates the safe use of this drug in clinical practice. From the prognostic point of view, pneumotoxicity is the most serious side effect of amiodarone therapy. «Amiodarone» pneumopathy refers to a dose-dependent variant and develops on average after 18-24 months of therapy. Interstitial lung involvement is considered the most frequent option. The clinical and radiologic picture is non-specific and requires careful analysis of the medical history. «Amiodarone» pneumopathy is a diagnosis that requires the elimination of infectious lesions of lung tissue and other possible causes of interstitial lung disease (ILD). With the purpose of early diagnosis of ILD in patients receiving amiodarone, computed tomography should be performed prior to the appointment of the drug and should be performed regularly every 6-12 months. In the case of the development of the «amiodarone» lung, amiodarone should be withdrawn, and therapy with prednisolone should be prescribed. With early diagnosis of amiodarone-induced lung injury and timely therapeutic intervention, the prognosis is favorable in most cases. The literature review is supplemented by three authors’ own observations of the late diagnosis of the «amiodarone» lung.

全文:

受限制的访问

作者简介

I. Trofimenko

Irkutsk State Medical Academy of Postgraduate Education (ISMAPGE) - Branch of RMACPE of RMH

Email: tin11@mail.ru
Department of Clinical Allergology and Pulmonology

B. Chernyak

Irkutsk State Medical Academy of Postgraduate Education (ISMAPGE) - Branch of RMACPE of RMH

MD, Associate Professor at the Department of Clinical Allergology and Pulmonology

参考

  1. Camus P., Rosenow E.C., editors. Drug-induced and iatrogenic respiratory disease. London MPG Books; 2010.
  2. Schwaiblmair M., Behr W., Haeckel T., Markl B., Foerg W, Berghaus T. Drug induced interstitial lung disease. Open Respir. Med. J. 2012;6:63-74.
  3. Camus P., Foucher P. The Drug-induced respiratory disease website. Available from: http://www.pneumotox.com. (Дата обращения 02.02.2018).
  4. Giardina E.G., Passman R. Clinical uses of amiodarone. 2017. Available from: https:// www.uptodate.com/contents/clinical-uses-of-amiodarone/ (Дата обращения 31.01.2018)
  5. Goldschlager N., Epstein A.E., Naccarelli G.V., Olshansky B., Singh B., Collard H.R., Murphy E. A practical guide for clinicians who treat patients with amiodarone: 2007. Heart Rhythm. 2007;4:1250-59.
  6. Okayasu K., Takeda Y., Kojima J. Amiodarone pulmonary toxicity: а patient with three recurrences of pulmonary toxicity and consideration of the probable risk of relapse. Intern. Med. 2006;45:1303-307.
  7. Vassallo P., Trohman R.G. Prescribing amiodarone. JAMA. 2007;298:1312-22.
  8. Singh V.K., Maheshwari V. Acute respiratory distress syndrome complicated by amiodarone induced pulmonary fibrosis: don't let your guard down. J. Clin. Diagn. Res. JCDR. 2017;11(4):UD01-UD02.
  9. Chan E.D., King T.E. Amiodarone pulmonary toxicity. 2017. Available from: https:// www.uptodate.com/contents/amiodarone-pulmonary-toxicity/contributors (Дата обращения 27.01.2018)
  10. Camus P., Fanton A., Bonniaud P., Camus C., Foucher P. interstitial lung disease induced by drugs and radiation. Respiration. 2004;71(4):301-26.
  11. Ernawati D.K., Stafford L., Hughes J.D. Amiodarone-induced pulmonary toxicity. Br. J. Clin. Pharmacol. 2008;66:82-7.
  12. Jackevicius C.A., Tom A., Essebag V., Eisenberg M.J., Rahme E., Tu J.V., Humphries K., Behlouli H., Pilote L. Population-level incidence and risk factors for pulmonary toxicity associated with amiodarone. Am. J. Cardiol. 2011; 108(5):705-10.
  13. Kang I.S., Kim K.J., Kim Y., Park S.H. The diagnostic utility of chest computed tomography scoring for the assessment of amiodarone-induced pulmonary toxicity. Korean J. Intern. Med. 2014;29(6):746-53.
  14. Sweidan A.J., Singh N.K., Dang N., Lam V., Datta J. Amiodarone-induced pulmonary toxicity -a frequently missed complication. Clin. Med. Insights Case Rep. 2016;9:91-4.
  15. Papiris S.A., Triantafillidou C., Kolilekas L., Markoulaki D., Manali E.D. Amiodarone: review of pulmonary effects and toxicity. Drug Saf. 2010;33(7):539-58.
  16. Baumann H., Fichtenkamm P., Schneider T., Biscoping J., Henrich M. Rapid onset of amiodarone induced pulmonary toxicity after lung lobe resection - A case report and re-view of recent literature. Ann. Med. Surg. (Lond). 2017;21:53-7.
  17. Hawatmeh A., Thawabi M., Jmeian A., Shaaban H., Shamoon F. Amiodarone-induced loculated pleural effusion without pulmonary parenchymal involvement: а case report and literature review. J. Nat. Sci. Biol. Med. 2017;8(1):130-33.
  18. Schwaiblmair M., Berghaus T., Haeckel T., Wagner T., von Scheidt W. Amiodarone-induced pulmonary toxicity: an under-recognized and severe adverse effect? Clin. Res. Cardiol. 2010; 99:693-700.
  19. Valle J.M., Alvarez D., Antunez J., Valdes L. Bronchiolitis obliterans organizing pneumo-nia secondary to amiodarone: a rare aetiology. Eur. Respir. J. 1995;8(3):470-1.
  20. Ott M.C., Khoor A., Leventhal J.P. Pulmonary toxicity in patients receiving low-dose Amiodarone. Chest. 2006;123:646-51.
  21. Fadahunsi O., Krol R. Acute amiodarone pulmonary toxicity following lung resection. Int. J. Biomed. Sci. 2014;10(3):217-20.
  22. Schindler K., Schima W., Kaliman J.F. Cryptogenic organizing pneumonia due to amioda-rone: long-term follow-up after corticosteroid treatment. Wien. Klin. Wochenschr. 2010;122(15-16):511-14.
  23. Myers J.L., Kennedy J.I., Plumb V.J. Amiodarone lung: pathologic findings in clinically toxic patients. Hum. Pathol. 1987;18:349-54.

补充文件

附件文件
动作
1. JATS XML
下载
##common.cookie##